Abstract 1130P
Background
Tebe, a bispecific T-cell engager, showed a benefit in response rate, progression-free survival (PFS) and overall survival (OS) in HLA A*02-01pos mUM pts in the IMCgp100-202 phase III trial. Prior to approval, French Health Authorities allowed an early access to Tebe in May 2021 to mUM pts. We report here our real-world experience with Tebe and analyses of potential prognostic and predictive biomarkers.
Methods
Ongoing ambispective cohort of mUM pts treated with Tebe. Tumor sizes were evaluated according to RECIST 1.1. Circulating tumor DNA (ctDNA) analyses were performed on this cohort and on the 18 pts enrolled in the IMCgp100-202 trial and randomized to Tebe, at Institut Curie. ctDNA was measured by digital droplet PCR (ddPCR) targeting codons 183 & 209 of both GNAQ and GNA11.
Results
72 pts were included from May 26th 2021 to December 12th 2022. With a median follow-up of 48 weeks, patients received a median of 22 weeks of Tebe. Out of 60 assessable pts, 33 (55%) showed stable disease and 5 (8%) partial response according to RECIST 1.1. Median PFS (mPFS) was 28 weeks (confidence interval 95% [CI95]: 8-56). OS at 12 months (OS12m) was 72%. No new, unexpected safety event occurred. Elevated baseline LDH was correlated with poorer OS (Spearman rho= -0.26, p<0.01). 63 pts had mUM carrying somatic mutations detectable by ddPCR (ie GNAQ/GNA11 mutations). Of these, 39 pts (62%) had detectable ctDNA at baseline. Pts with detectable ctDNA at baseline had poorer PFS (mPFS 4.0 vs 14.0 months; HR=2.83, CI95[1.48-5.41]) and OS (OS12m of 51.5% vs 95.4%; HR=6.11, CI95[2.04-18.3]) than those with undetectable ctDNA. 22 pts cleared their ctDNA at first assessment (12 weeks) and had numerically better OS12m than those who did not (70% vs 60%; HR = 1.83 CI95[0.92-13.9]).
Conclusions
In this real-world cohort of mUM pts, Tebe is associated with clinical outcomes in lin withthe IMCgp100-202 trial. Baseline ctDNA and LDH are prognostic factors while ctDNA clearance might predict benefit from Tebe. Other analyses are ongoing to identify new predictive biomarkers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
INSERM.
Disclosure
M. Saint-Ghislain: Financial Interests, Invited Speaker: Oncotream. J. Thery: Financial Interests, Invited Speaker: PharmaMar; Financial Interests, Advisory Board: Pfizer, AstraZeneca. P. Combe: Financial Interests, Invited Speaker: Eisai, BMS GmbH&Co.KG, Novartis, Clovis Oncology, AstraZeneca. C. Dutriaux: Financial Interests, Advisory Board: Bristol Myers Squibb, MSD, Pierre Fabre. S. Piperno-Neumann: Financial Interests, Personal, Advisory Board: Immunocore, Pierre Fabre, Atlanthera. M.J. Rodrigues: Financial Interests, Personal, Invited Speaker: Immunocore; Financial Interests, Personal, Advisory Board: GSK, AstraZeneca; Financial Interests, Institutional, Coordinating PI: Johnson & Johnson; Non-Financial Interests, Institutional, Product Samples: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1169P - Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Presenter: Martha Estefania Vázquez-Cruz
Session: Poster session 13
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13